WAVE Life Sciences Ltd. WVE
3.78
(0.18)
(4.55%)
as of 25 Sep
- Market cap
- $780.3M
- P/E
- 0.0×
Follow WVE
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
11.24 | 67.10 | 20.21 | 18.13 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(27.49) | (84.88) | (24.37) | (22.12) | |
P/B ratio |
9.86 | 5.53 | 2.84 | 2.61 | |
Price to Tangible BV |
9.86 | 5.53 | 2.84 | 2.61 | |
EV/Sales |
9.69 | 53.65 | 13.01 | 11.04 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(5.36) | (12.23) | (5.07) | (3.77) | |
EV/FCF |
(5.34) | (12.18) | (5.05) | (3.74) | |
Quick Ratio |
2.40 | 6.35 | 10.93 | 9.67 | |
Current Ratio |
2.51 | 6.47 | 11.26 | 9.99 | |
Net Debt/EBITDA |
3.63 | 11.11 | 18.78 | 6.87 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.36 | 0.09 | 0.16 | 0.16 | |
Operating CF/Net income |
0.83 | 0.64 | 2.28 | 0.77 | |
Capex/Depreciation |
(0.11) | 0.00 | (0.19) | (0.37) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
602.97% | 306.26% | 124.04% | 2,257.61% | |
Selling, General and Administrative Expense of Revenue |
237.74% | 121.18% | 57.79% | 1,090.71% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
85.07% | 42.63% | 23.70% | 472.40% | |
Graham Net Nets |
0.08 | 0.17 | 0.34 | 0.34 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(10.11%) | (7.18%) | (14.62%) | (18.76%) | |
Free Cash Flow Yield |
(16.14%) | (6.56%) | (12.75%) | (16.30%) | |
Revenue per Share |
0.05 | 0.10 | 0.19 | 0.01 | |
Operating CF per Share |
(0.27) | (0.20) | (0.30) | (0.26) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.27) | (0.20) | (0.30) | (0.27) | |
Cash per Share |
1.17 | 3.57 | 2.72 | 2.40 | |
Shareholders Equity per Share |
0.74 | 3.07 | 2.56 | 2.22 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.74 | 3.07 | 2.56 | 2.22 | |
Free Cash Flow |
(44.91) | (33.77) | (59.99) | (54.47) | |
Working Capital |
129.59 | 519.75 | 511.44 | 456.69 | |
Capital Expenditures |
(0.25) | 0.00 | (0.44) | (0.88) | |
Net Current Asset Value |
98.66 | 494.67 | 489.46 | 402.71 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.03 | 0.00 | 0.01 | 0.39 | |
Net Profit Margin |
(707.83%) | (308.37%) | (68.21%) | (3,052.60%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
15.54 | 1.28 | — | 1.16 | |
Average Payables |
13.64 | 15.98 | 16.71 | 17.51 | |
Average Assets |
299.94 | 495.35 | 435.94 | 405.34 | |
Average Common Equity |
133.09 | 363.94 | 341.77 | 296.39 |
Columns are period end dates